Back to top

Top Ranked Momentum Stocks to Buy for May 14th

Read MoreHide Full Article

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 14th:

Twin Disc, Incorporated (TWIN - Free Report) : This designer of power transmission equipment has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings advancing more than 100% over the last 60 days.

Twin Disc, Incorporated Price and Consensus

Twin Disc’s shares gained 26.4% over the last one month more than S&P 500’s gain of 0.8%. The company possesses a Momentum Score of A.

Twin Disc, Incorporated Price

DMC Global Inc. (BOOM - Free Report) : This technology company has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 52.4% over the last 60 days.

DMC Global Inc. Price and Consensus

DMC Global’s shares gained 42.2% over the last one month. The company possesses a Momentum Score of B.

DMC Global Inc. Price

Boise Cascade Company (BCC - Free Report) : This manufacturer of wood products has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings advancing 30% over the last 60 days.

Boise Cascade, L.L.C. Price and Consensus

Boise Cascade’s shares gained 2% over the last one month. The company possesses a Momentum Score of B.

Boise Cascade, L.L.C. Price

Delta Apparel, Inc. (DLA - Free Report) : This apparel manufacturer has a Zacks Rank #1 (Strong Buy) and witnessed the Zacks Consensus Estimate for its current year earnings advancing 11.1% over the last 60 days.

Delta Apparel, Inc. Price and Consensus

Delta Apparel’s shares gained 8.5% over the last one month. The company possesses a Momentum Score of A.

Delta Apparel, Inc. Price

See the full list of top ranked stocks here

Learn more about the Momentum score and how it is calculated here.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>



More from Zacks Zacks #1 Rank Additions

You May Like